Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML), a significant proportion will not achieve optimal response to imatinib or second-generation tyrosine kinase inhibitors (2GTKI). For patients with inadequate response to 2GTKIs, alternative 2GTKIs or ponatini...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Gutiérrez, Valentín, Hernández-Boluda, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408792/
https://www.ncbi.nlm.nih.gov/pubmed/32679880
http://dx.doi.org/10.3390/jcm9072251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408792/
https://www.ncbi.nlm.nih.gov/pubmed/32679880
http://dx.doi.org/10.3390/jcm9072251

Ejemplares similares